Patent ID: 6060047
Filing Date: 2000-05-09
Classification: A61K,A61P,C07K

Abstract:
A method of treating a patient having a hematopoietic disorder comprising; administering to said patient a therapeutically effective amount of a composition comprising;a modified human interleukin-3 (hIL-3) amino acid sequence, wherein said modified sequence differs from the sequence of native (1-133) hIL-3 by the replacement of from 4 to about 44 of the residues corresponding to positions 17-123 of native (1-133) hIL-3 by other amino acids, with the proviso that the residues corresponding to positions 101 and 116 are not Ala or Val, respectively; wherein said modified sequence optionally further differs from the sequence of native (1-133) hIL-3 by the deletion of from 1 to 14 residues from the N-terminus of native (1-133) hIL-3, the deletion of from 1 to 15 residues from the C-terminus of native (1-133) hIL-3, or both; and wherein said modified interleukin-3 (hIL-3) amino acid sequence has at least three times greater activity, relative to native human interleukin-3, in at least one assay selected from the group consisting of: AML cell proliferation, TF-1 cell proliferation and Methylcellulose assay; anda factor selected from the group consisting of: a colony stimulating factor, a cytokine a lymphokine, an interleukin and a hematopoietic growth factor.